These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 8840326

  • 1. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study.
    Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E.
    Nephrol Dial Transplant; 1996; 11 Suppl 3():121-4. PubMed ID: 8840326
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
    Tamura S, Ueki K, Mashimo K, Tsukada Y, Naitoh M, Abe Y, Kawai H, Tsuchida A, Wakamatsu R, Nojima Y.
    Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study.
    Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, Slatopolsky E, Kurokawa K.
    Nephrol Dial Transplant; 2002 Sep; 17 Suppl 10():28-36. PubMed ID: 12386266
    [Abstract] [Full Text] [Related]

  • 6. Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism.
    Kinugasa E, Akizawa T, Takahashi J, Nabeshima K, Ogata H, Nakayama F, Ideura T.
    Nephrol Dial Transplant; 2002 Sep; 17 Suppl 10():20-7. PubMed ID: 12386265
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, Taguchi S.
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [Abstract] [Full Text] [Related]

  • 9. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.
    Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K.
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S147-51. PubMed ID: 11576942
    [Abstract] [Full Text] [Related]

  • 10. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
    Doi S, Yorioka N, Usui K, Shigemoto K, Harada S.
    Intern Med; 2003 Oct; 42(10):955-9. PubMed ID: 14606707
    [Abstract] [Full Text] [Related]

  • 11. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y.
    Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
    [Abstract] [Full Text] [Related]

  • 12. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism.
    Malberti F, Surian M, Cosci P.
    Nephrol Dial Transplant; 1992 Aug; 7(8):822-8. PubMed ID: 1325615
    [Abstract] [Full Text] [Related]

  • 13. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism.
    Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y.
    Am J Kidney Dis; 2000 Mar; 35(3):458-64. PubMed ID: 10692271
    [Abstract] [Full Text] [Related]

  • 14. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH, Chiang SS, Tsai SC, Chang CC, Wu SC, Shieh SD, Huang TP.
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705
    [Abstract] [Full Text] [Related]

  • 15. Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.
    Honda H, Koiwa F, Ogata H, Shishido K, Sekiguchi T, Michihata T, Ogawa H, Mukai M, Takahashi K, Suzuki R, Kino K, Kato K, Yamamoto K, Kinugasa E, Akizawa T.
    Int J Clin Pharmacol Ther; 2014 May; 52(5):360-8. PubMed ID: 24569127
    [Abstract] [Full Text] [Related]

  • 16. [Calcitriol dose optimization in the treatment of secondary hyperparathyroidism during dialysis. Results at 6 months].
    Rodríguez García M, Fernández Martín JL, Ruiz de Castañeda J, Hervás Sánchez J, Cannata Andía JB, Grupo de Estudio Caldial.
    Nefrologia; 2002 May; 22(4):370-6. PubMed ID: 12369129
    [Abstract] [Full Text] [Related]

  • 17. The effect of intraperitoneal 22-oxacalcitriol on secondary hyperparathyroidism in continuous ambulatory peritoneal dialysis patients (IPOX study).
    Kubota M, Iwanaga Y, Ishiguro N.
    Adv Perit Dial; 2003 May; 19():227-30. PubMed ID: 14763068
    [Abstract] [Full Text] [Related]

  • 18. Vitamin D analogues for secondary hyperparathyroidism.
    Brown AJ, Dusso AS, Slatopolsky E.
    Nephrol Dial Transplant; 2002 May; 17 Suppl 10():10-9. PubMed ID: 12386264
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S.
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.